Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors
- 1 September 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Urology
- Vol. 18 (5), 533-539
- https://doi.org/10.1097/mou.0b013e32830b8910
Abstract
The diagnosis and treatment of bladder cancer represents a significant financial burden to the population in the United States. Therapeutic advances in bladder cancer care have come at a high cost to payers, providers, and patients. This study describes the principals of cost-effectiveness evaluation in healthcare and provides recommendations for a more economical use of resources in bladder cancer care. Although several studies have demonstrated that bladder cancer is a common disease associated with substantial economic burden for patients and society, the evidence supporting the cost-effectiveness of many interventions in bladder cancer care is limited and of insufficient quality. In addition, very little is known about quality of life, the preferred outcome measure for economic evaluations, associated with bladder cancer states and treatments. Moreover, current clinical guidelines for bladder cancer care do not incorporate economic factors when evaluating clinical pathways. Although cost-effectiveness studies in bladder cancer could allow us to know how healthcare dollars are being spent and assist in determining more effective ways to allocate resources, most of the currently used interventions have not undergone economic assessment.Keywords
This publication has 35 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancerCurrent Opinion in Urology, 2007
- Recent developments in fluorescence cystoscopy: do novel agents bring a benefit?Current Opinion in Urology, 2007
- The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgeryCurrent Opinion in Urology, 2007
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Orthotopic bladder reconstruction in women—what we have learned over the last decadeCritical Reviews in Oncology/Hematology, 2003
- The Role of Perspective in Defining Economic Measures for the Evaluation of Medical TechnologyInternational Journal of Technology Assessment in Health Care, 1996
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Opportunity Costs In Modern MedicineHealth Affairs, 1992
- Estimating Costs in the Economic Evaluation of Medical TechnologiesInternational Journal of Technology Assessment in Health Care, 1990